ArticleCureus2025

Anaplastic Lymphoma Kinase (ALK) Fusion as a Resistance Mechanism to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors With Complete Response After Osimertinib and Alectinib: A Case Report and Literature Review.

Ben Man Fei Cheung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.